David W Dodick

Apr 25, 2024 | journals.sagepub.com | DAVID WHITAKER |Gina Dumkrieger |Joseph Hentz |David W Dodick

IntroductionThe World Health Organization ranks migraine as the second leading cause of disability measured in years lived with disability (YLDs), accounting for 41.1 million YLDs in 2019, 4.8% of all YLDs globally (1). Physical impairment during and between migraine attacks constitutes a key dimension of migraine-associated disability (2). While much of the disability resulting from migraine occurs during migraine attacks, disability can persist between migraine attacks.

Nov 15, 2023 | thelancet.com | David W Dodick |Peter J Goadsby

Summary Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for acute treatment of migraine. The prodrome is the earliest phase of a migraine attack and is characterised by non-aura symptoms that precede headache onset. The aim of this trial was to evaluate the efficacy, safety, and tolerability of ubrogepant 100 mg compared with placebo for the acute treatment of migraine when administered during the prodrome.

Jul 24, 2023 | jamanetwork.com | Frank Porreca |Mayo Clinic Arizona |David W Dodick

Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine Migraine is the world’s most common neurological disorder, affecting approximately 1 billion people worldwide, the great majority of whom (approximately 700 million) are women. This female predominance is reflected in the clinic and in clinical trials, where most patients (~85%) are women.

Jun 29, 2023 | thelancet.com | Wolfgang Grisold |David W Dodick |Steven Lewis

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.